Valve performance also improved over time. By day 30, 83.3% of patients had achieved no or trace regurgitation. This climbed to 91.8% at 1 year and 95.6% at 2 years, Vahl reported. At enrollment ...

Trace Medicine has launched with $101 million in series A funds and a mission to treat amyotrophic lateral sclerosis (ALS) by targeting the same protein that recently caught the attention of Eli ...

Yes! I want to get the latest chemistry news from C&EN in my inbox every week. ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly ...

Trace Neuroscience launched on Tuesday to announce that it is developing a genetic treatment targeting UNC13A, a gene linked to both a higher risk of ALS and faster disease progression.

Degenerative mitral valve disease is common. Up to a quarter of patients with degenerative mitral valve disease may be asymptomatic despite having severe valve regurgitation. Current guideline ...